Natco Pharma Ltd (NATCOPHARM)

Natco Pharma Ltd's Q3FY24 Revenue Grows by 54.26% - 29 Apr, 2024

Natco Pharma Limited reported a revenue growth of 54.26% in Q3FY24, with profits increasing from Rs. 62 Crores to Rs. 213 Crores. Additionally, FII/FPI increased their stake in the company by 2.42%.

Natco Pharma Receives EIR from USFDA and Target Price Raised by Investec - 23 Apr, 2024

Natco Pharma has received the Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA), concluding a successful inspection with zero observations. Investec has maintained a buy rating on the company and raised its target price to Rs 1200 from Rs 710 earlier.

Natco Pharma Receives USFDA Warning Letter - 22 Apr, 2024

The US FDA has issued a warning letter to Natco Pharma for failing to maintain cleanliness and sterilize equipment at its Telangana-based plant. The company also failed to investigate discrepancies or failures of batches to meet specifications. The FDA has requested an independent assessment of the company's overall system for investigating deviations, complaints, out-of-specification results, and records management.

Natco Pharma Faces Legal Challenge Over Marketing of Diazepam Injection Prefilled Syringe - 18 Apr, 2024

Natco Pharma faces legal action from Fresenius Kabi USA and Fresenius Kabi Deutschland over the marketing of its Diazepam Injection prefilled syringe. Meanwhile, insiders own 50% of the company's shares, with Top Key Executive Venkaiah Nannapaneni holding the largest stake.

Natco Pharma Patent Infringement Suits Transferred to Delhi HC - 17 Apr, 2024

The Supreme Court has transferred the patent infringement suits filed by Natco Pharma from Chandigarh district commercial court to the Delhi High Court. Meanwhile, foreign institutional investors have increased their stake in the company during Q4FY24.

Natco Pharma Reports Strong Q3FY24 Results - 11 Apr, 2024

Natco Pharma reported a 54% increase in revenue and a 243% increase in net profit for Q3FY24 compared to the same period last year. The R&D-focused pharmaceutical firm develops, manufactures, and markets complicated pharmaceuticals in specialty therapeutic areas.

Natco Pharma Receives Warning Letter from USFDA - 10 Apr, 2024

Natco Pharma has received a warning letter from the US Food and Drug Administration (USFDA) for its Telangana-based manufacturing plant. The inspection was conducted in October 2023, and the company had received eight observations under Form 483. Natco Pharma does not believe that the warning letter will impact supplies or existing revenues but may cause delay/withholding of pending product approvals from this site.

Natco Pharma Receives Warning Letter from USFDA - 09 Apr, 2024

Natco Pharma has received a warning letter from the USFDA for its Kothur-based manufacturing facility. The company does not anticipate any disruption to supplies or existing revenues, but there may be delays in pending product approvals. The stock dropped over 2% on BSE. Nuvama Institutional Equities noted that generic Revlimid will benefit companies such as Natco, Zydus Lifesciences, Sun Pharmaceutical Industries, DRL, and Aurobindo.